AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP cut its position in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 67.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,608 shares of the biotechnology company's stock after selling 64,364 shares during the quarter. Dimensional Fund Advisors LP owned 0.10% of AnaptysBio worth $418,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new position in shares of AnaptysBio in the fourth quarter valued at approximately $40,000. AlphaQuest LLC boosted its position in AnaptysBio by 1,891.5% in the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after buying an additional 4,237 shares during the period. Russell Investments Group Ltd. grew its stake in shares of AnaptysBio by 1,585.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock worth $75,000 after acquiring an additional 5,360 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of AnaptysBio by 11.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 644 shares during the period. Finally, Aristides Capital LLC acquired a new stake in shares of AnaptysBio in the fourth quarter valued at $168,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. HC Wainwright restated a "neutral" rating and set a $22.00 price target on shares of AnaptysBio in a report on Tuesday, March 4th. Johnson Rice reissued a "buy" rating on shares of AnaptysBio in a research report on Wednesday, March 26th. Wells Fargo & Company raised their target price on shares of AnaptysBio from $40.00 to $51.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Wolfe Research began coverage on shares of AnaptysBio in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 price objective on the stock. Finally, Guggenheim boosted their target price on shares of AnaptysBio from $52.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $35.88.

AnaptysBio Trading Up 1.2%

Shares of NASDAQ ANAB traded up $0.25 during trading hours on Monday, reaching $20.47. The stock had a trading volume of 434,133 shares, compared to its average volume of 600,688. The firm has a 50-day moving average of $18.97 and a 200-day moving average of $18.24. The firm has a market cap of $601.41 million, a price-to-earnings ratio of -3.37 and a beta of -0.20. AnaptysBio, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.30) by $0.02. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The business had revenue of $27.77 million for the quarter, compared to analyst estimates of $15.27 million. On average, equities analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio declared that its board has initiated a share buyback program on Monday, March 24th that authorizes the company to buyback $75.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to buy up to 13.1% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's leadership believes its stock is undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.